Several predictors of resistance have been described and include the patients’ gender, age, initial GH and IGF-1 levels, tumor volume, tumor hyperintensity on T2-weighted magnetic resonance imaging, and the expression of somatostatin receptor subtypes [7]. The gene discussed is GH1; the disease is neoplasm.